Merck acquires Bangalore Genei

German multinational drug major has acquired (India) Pvt Ltd (BGIP), which specialises in new generation proteomic and genomic research technologies, the cutting-edge study of proteins and organisms. Merck, which acquired the company through its wholly-owned Indian subsidiary, Merck Specialities Private, did not disclose the deal’s size.

Merck is a global pharmaceutical and chemical company which had total revenues of ¤7.6 billion in 2008. It has a manufacturing facility at Goa and is the largest manufacturer of Vitamin E in India. Merck Specialities supplies pharmaceutical and chemical products.

BGIP is a part of the Chennai-based speciality chemicals major, Sanmar Group. It has 100 employees and had generated total revenues of Rs 20.2 crore in 2008-09, according to a press release. By combining BGIP’s activities with Merck’s existing bioscience business, Merck will become one of the leading bioscience in India, the release added.

“BGIP’s leadership in the Indian academic market, a segment with high growth potential, will ideally complement our existing customer base. BGIP’s product portfolio comprises a wide range of bioscience products, which are tailored to the needs of the domestic market in India.” said Christina Shasserre, global head of Merck’s bioscience business.

image
Business Standard
177 22
Business Standard

Merck acquires Bangalore Genei

BS Reporter  |  Mumbai 

German multinational drug major has acquired (India) Pvt Ltd (BGIP), which specialises in new generation proteomic and genomic research technologies, the cutting-edge study of proteins and organisms. Merck, which acquired the company through its wholly-owned Indian subsidiary, Merck Specialities Private, did not disclose the deal’s size.

Merck is a global pharmaceutical and chemical company which had total revenues of ¤7.6 billion in 2008. It has a manufacturing facility at Goa and is the largest manufacturer of Vitamin E in India. Merck Specialities supplies pharmaceutical and chemical products.

BGIP is a part of the Chennai-based speciality chemicals major, Sanmar Group. It has 100 employees and had generated total revenues of Rs 20.2 crore in 2008-09, according to a press release. By combining BGIP’s activities with Merck’s existing bioscience business, Merck will become one of the leading bioscience in India, the release added.

“BGIP’s leadership in the Indian academic market, a segment with high growth potential, will ideally complement our existing customer base. BGIP’s product portfolio comprises a wide range of bioscience products, which are tailored to the needs of the domestic market in India.” said Christina Shasserre, global head of Merck’s bioscience business.

RECOMMENDED FOR YOU

Merck acquires Bangalore Genei

German multinational drug major Merck KGaA has acquired Bangalore Genei (India) Pvt Ltd (BGIP), which specialises in new generation proteomic and genomic research technologies, the cutting-edge study of proteins and organisms. Merck, which acquired the company through its wholly-owned Indian subsidiary, Merck Specialities Private, did not disclose the deal’s size.

German multinational drug major has acquired (India) Pvt Ltd (BGIP), which specialises in new generation proteomic and genomic research technologies, the cutting-edge study of proteins and organisms. Merck, which acquired the company through its wholly-owned Indian subsidiary, Merck Specialities Private, did not disclose the deal’s size.

Merck is a global pharmaceutical and chemical company which had total revenues of ¤7.6 billion in 2008. It has a manufacturing facility at Goa and is the largest manufacturer of Vitamin E in India. Merck Specialities supplies pharmaceutical and chemical products.

BGIP is a part of the Chennai-based speciality chemicals major, Sanmar Group. It has 100 employees and had generated total revenues of Rs 20.2 crore in 2008-09, according to a press release. By combining BGIP’s activities with Merck’s existing bioscience business, Merck will become one of the leading bioscience in India, the release added.

“BGIP’s leadership in the Indian academic market, a segment with high growth potential, will ideally complement our existing customer base. BGIP’s product portfolio comprises a wide range of bioscience products, which are tailored to the needs of the domestic market in India.” said Christina Shasserre, global head of Merck’s bioscience business.

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard